biotech · Parkinson Disease · Amyotrophic Lateral Sclerosis · DNLI
Denali Therapeutics
Denali Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker DNLI. Primary therapeutic focus areas include Parkinson Disease, Amyotrophic Lateral Sclerosis, Fron
161 Oyster Point Blvd, South San Francisco, California 94080, US HQ
2015 Founded
567 Employees
Public company Type
DNLI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 161 Oyster Point Blvd, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 567
- Programs
- 23
- Drugs
- 10
- Patents
- 42
tividenofusp alfa
Phase 3 · small molecule · Mucopolysaccharidosis II
tividenofusp alfa for Mucopolysaccharidosis II is a Phase 3 program (small_molecule) at Denali Therapeutics with 3 ClinicalTrials.gov record(s).
Internal code DNLI-E-0008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Denali Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Mucopolysaccharidosis II
- Status
- active
- Trials
- 3